New hope for advanced prostate cancer patients, with promising new drug combo that targets genes, such as BRCA1, BRCA2, CHEK2 ...

Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy.

Winship Cancer Institute of Emory University, a nonprofit medical research center based out of Atlanta, has launched a new mobile prostate cancer screening program. Backed by the Arthur M. Blank ...

Researchers at Wayne State University and the Barbara Ann Karmanos Cancer Institute have developed a chemical imaging probe ...

DURHAM, N.C. (WTVD) -- Researchers at Duke Cancer Institute are sharing new developments when it comes to prostate cancer therapy. According to the American Cancer Society, there are more than 200,000 ...

A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...

Driven by increased life expectancy and related changes in age structure, global prostate cancer cases will more than double over the next 15 years, a panel of experts concluded. The number of new ...

Study links higher expression of the gene PROX1 to aggressive change in prostate tumor cells; FDA-approved class of drugs can disable PROX1 ANN ARBOR, Michigan — Researchers at the University of ...

Doug pedals fast, feeling the exhilaration of speeding along a bike track as his heart rate rises and he starts to breathe harder. Since being diagnosed with stage 4 metastatic prostate cancer in ...

According to the American Cancer Society, prostate cancer is one of the leading types of cancer in men in the United States. An estimated 1 in 8 men will be diagnosed with the disease. Receiving a ...

Not all cancers are alike, especially when it comes to prostate cancer. “Most patients are diagnosed with a low- or favorable intermediate-risk prostate cancer,” said Fred Hutch Cancer Center genetic ...